Immunome, Inc.(IMNM)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Immunome has transitioned into a high-intensity clinical development phase, characterized by the total evaporation of legacy collaboration revenue and a shift toward internal antibody-drug conjugate research.
• While the company maintains a substantial liquidity buffer of $582.7 million in cash as of 2026Q1, the lack of a commercial engine and persistent quarterly operating losses exceeding $50 million suggest significant long-term execution risk.
• Investors should monitor the sustainability of this capital-intensive model, as the accumulation of retained earnings losses totaling -$782.0 million underscores the ongoing erosion of shareholder value.